

Table SIII. Hazard ratio (HR) for flares when having Psoriasis Area and Severity Index (PASI) =0 as reference for patients treated with adalimumab, etanercept, infliximab, and ustekinumab

	Unadjusted HR (95% CI)	p-value	Adjusted for sex and age HR (95% CI)	p-value	Fully adjusted* HR (95% CI)	p-value
Adalimumab						
Flare (PASI ≥3)						
PASI=0	Ref.	-	Ref.	-	Ref.	-
PASI >0-≤2	1.41 (1.02-1.97)	0.039	1.44 (1.04-2.01)	0.030	1.36 (0.97-1.90)	0.07
PASI >2-≤4	2.33 (1.59-3.40)	<0.0001	2.39 (1.63-3.50)	<0.0001	2.18 (1.48-3.22)	<0.0001
PASI >4	1.80 (1.16-2.80)	0.0090	1.88 (1.22-2.91)	0.0045	1.67 (1.06-2.65)	0.028
Flare (PASI ≥5)						
PASI=0	Ref.	-	Ref.	-	Ref.	-
PASI >0-≤2	1.20 (0.73-1.96)	0.48	1.23 (0.75-2.02)	0.41	1.22 (0.74-2.01)	0.44
PASI >2-≤4	2.35 (1.39-3.96)	0.0014	2.42 (1.43-4.10)	0.0010	2.47 (1.44-4.23)	0.0010
PASI >4	1.85 (1.00-3.43)	0.05	2.00 (1.07-3.73)	0.029	2.11 (1.10-4.02)	0.024
Etanercept						
Flare (PASI ≥3)						
PASI=0	Ref.	-	Ref.	-	Ref.	-
PASI >0-≤2	0.83 (0.45-1.53)	0.55	0.82 (0.45-1.51)	0.52	0.80 (0.43-1.48)	0.47
PASI >2-≤4	1.28 (0.71-2.33)	0.41	1.26 (0.69-2.29)	0.45	1.20 (0.65-2.23)	0.56
PASI >4	1.68 (0.92-3.07)	0.09	1.67 (0.91-3.06)	0.10	1.56 (0.81-3.01)	0.18
Flare (PASI ≥5)						
PASI=0	Ref.	-	Ref.	-	Ref.	-
PASI >0-≤2	0.84 (0.30-2.33)	0.74	0.84 (0.30-2.33)	0.74	0.83 (0.30-2.33)	0.72
PASI >2-≤4	1.02 (0.36-2.92)	0.97	1.04 (0.36-2.98)	0.94	0.97 (0.33-2.85)	0.95
PASI >4	2.72 (1.08-6.82)	0.033	2.77 (1.10-6.97)	0.030	2.54 (0.95-6.76)	0.06
Infliximab						
Flare (PASI ≥3)						
PASI=0	Ref.	-	Ref.	-	Ref.	-
PASI >0-≤2	2.96 (1.35-6.47)	0.0066	2.95 (1.33-6.54)	0.0077	3.22 (1.33-7.77)	0.0095
PASI >2-≤4	1.72 (0.60-4.97)	0.32	1.66 (0.57-4.83)	0.35	1.63 (0.49-5.44)	0.43
PASI >4	3.61 (1.41-9.22)	0.0074	3.09 (1.16-8.24)	0.024	2.68 (0.92-7.78)	0.07
Flare (PASI ≥5)						
PASI=0	Ref.	-	Ref.	-	Ref.	-
PASI >0-≤2	4.28 (1.33-14.1)	0.015	4.63 (1.37-15.6)	0.014	4.68 (1.20-18.3)	0.026
PASI >2-≤4	0.92 (0.10-8.24)	0.94	0.89 (0.10-8.09)	0.92	1.11 (0.10-11.9)	0.93
PASI >4	0.85 (0.09-7.72)	0.89	0.86 (0.09-8.06)	0.90	0.69 (0.07-6.85)	0.75
Ustekinumab						
Flare (PASI ≥3)						
PASI=0	Ref.	-	Ref.	-	Ref.	-
PASI >0-≤2	1.12 (0.71-1.77)	0.63	1.12 (0.71-1.77)	0.63	1.07 (0.67-1.70)	0.78
PASI >2-≤4	3.06 (1.96-4.77)	<0.0001	2.97 (1.89-4.50)	<0.0001	2.82 (1.80-4.42)	<0.0001
PASI >4	3.89 (2.39-6.33)	<0.0001	3.82 (2.34-6.24)	<0.0001	3.66 (2.22-6.03)	<0.0001
Flare (PASI ≥5)						
PASI=0	Ref.	-	Ref.	-	Ref.	-
PASI >0-≤2	1.54 (0.70-3.37)	0.28	1.56 (0.71-3.43)	0.26	1.50 (0.68-3.33)	0.32
PASI >2-≤4	6.43 (3.22-12.9)	<0.0001	6.96 (3.45-14.0)	<0.0001	6.50 (3.20-13.2)	<0.0001
PASI >4	6.97 (3.29-14.7)	<0.0001	7.51 (3.53-16.0)	<0.0001	7.70 (3.53-16.8)	<0.0001
Secukinumab						
Flare (PASI ≥3)						
PASI=0	Ref.	-	Ref.	-	Ref.	-
PASI >0-≤2	2.49 (0.81-7.63)	0.11	2.53 (0.82-7.77)	0.11	2.04 (0.61-6.89)	0.25
PASI >2-≤4	14.1 (3.63-54.8)	0.0001	15.5 (3.49-67.9)	0.0003	18.7 (3.83-90.9)	0.0003
PASI >4	3.52 (0.44-28.2)	0.24	3.72 (0.46-30.1)	0.22	2.04 (0.22-18.8)	0.53

Analysis for flare defined as PASI ≥5 was not done due to too few patients.

*Adjusted for sex, age, methotrexate, psoriatic arthritis, body weight, and hospital.

Ref.: reference group; 95% CI: 95% confidence interval.